Iran War Pharma Shock: Why India’s API Dependence Hurts More Than China’s Biotech Lead
Iran War Pharma Shock: India API Dependence vs China Biotech Chokepoints | Witfire Elite View Witfire Elite Pharma Markets Case Studies Strategy Long Read Pharma Market Case Studies Witfire Elite View Iran War Pharma Shock Why India’s API Dependence Hurts More Than China’s Biotech Lead The Iran war and Strait of Hormuz disruption expose a deeper pharma asymmetry: India dominates…
Trending News
Pharma Stock Market News: US-Israel-Iran War Impact on Drug Supply Chains, Oil Prices and Healthcare Stocks
The stock market is now looking at the US-Israel-Iran conflict through a sharper…
Pharma Stock Market News: US-Israel-Iran War Impact on Drug Companies, Oil Prices, and Pharma Supply Chains
The US-Israel-Iran war is affecting pharma stocks, drug supply chains, logistics costs, cold-chain…
Lilly’s Germany Investment Cut: Why Pharma Capital Is Starting to Vote Against Policy Risk
Lilly’s Germany Investment Cut: Why Pharma Capital Is Starting to Vote Against Policy…
Iran War Pharma Shock: Why India’s API Dependence Hurts More Than China’s Biotech Lead
Iran War Pharma Shock: India API Dependence vs China Biotech Chokepoints | Witfire…
Editorial picks
Iran War Pharma Shock: Why India’s API Dependence Hurts More Than China’s Biotech Lead
CagriSema May Not Be Enough to Restore Novo Nordisk’s Obesity Lead
India’s Generic Ozempic Boom Is a Margin Trap—and the Price Collapse It Started Has Now Reached the US
Eli Lilly Retatrutide Phase 3 Results at ADA 2026
Iran War Pharma Shock: Why India’s API Dependence Hurts More Than China’s Biotech Lead
Iran War Pharma Shock: India API Dependence vs China Biotech Chokepoints | Witfire Elite View Witfire Elite Pharma Markets Case Studies Strategy Long Read Pharma Market Case Studies Witfire Elite View Iran War Pharma Shock Why India’s API Dependence Hurts More Than China’s Biotech Lead The Iran war and Strait…
Lilly’s Germany Investment Cut: Why Pharma Capital Is Starting to Vote Against Policy Risk
Iran War Pharma Shock: Why India’s API Dependence Hurts More Than China’s Biotech Lead
IQVIA Wegovy Pill Data and Oral GLP-1 Market Expansion
IQVIA Signal: Wegovy Pill May Expand the GLP-1 Market, Not Just Replace Injections
Categories
Investments
business news
Entrepreneurship
Startups
2026
INSIGHTS FOR THE NEW PHARMA LEADERS
Witfire Elite brings focused perspectives on pharma growth, innovation, manufacturing, startups, and executive strategy.
Around The World
India’s Generic Ozempic Boom Is a Margin Trap—and the Price Collapse It Started Has Now Reached the US
Witfire Elite View · Pharma Market Case Study · Updated 12 June 2026 The cheapest semaglutide in the world is made in India — and the price collapse it triggered is now reaching the United States. Roughly three months after Novo Nordisk’s core Indian patent expired and more than 40 local drugmakers flooded the market with generic Ozempic and Wegovy…
Pharma News
Iran War Pharma Shock: Why India’s API Dependence Hurts More Than China’s Biotech Lead
Iran War Pharma Shock: India API Dependence vs China Biotech Chokepoints | Witfire Elite View Witfire Elite Pharma…
CagriSema May Not Be Enough to Restore Novo Nordisk’s Obesity Lead
Novo Nordisk did not lose momentum because CagriSema is a weak drug. That is too simple. The sharper…
India’s Generic Ozempic Boom Is a Margin Trap—and the Price Collapse It Started Has Now Reached the US
Witfire Elite View · Pharma Market Case Study · Updated 12 June 2026 The cheapest semaglutide in the…